You have 9 free searches left this month | for more free features.

s-1

Showing 1 - 25 of 99

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)

Recruiting
  • Gastric Cancer
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 7, 2023

Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin
  • +3 more
  • (no location specified)
Nov 17, 2022

Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)

Not yet recruiting
  • Immunotherapy Gastrict Cancer
  • (no location specified)
Jan 17, 2023

Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract

Recruiting
  • Biliary Tract Neoplasms
  • +3 more
  • Shanghai, China
    Huashan hospital
Aug 16, 2022

Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)

Recruiting
  • Advanced Gastroesophageal Adenocarcinoma
  • Beijing, China
  • +2 more
Sep 14, 2022

Gastric Cancer Trial in Beijing (S-1, Trastuzumab, Oxaliplatin)

Completed
  • Gastric Cancer
  • S-1
  • +3 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences
Aug 14, 2022

Locally Advanced or Metastatic Pancreatic Cancer Trial (S-1)

Completed
  • Locally Advanced or Metastatic Pancreatic Cancer
  • S-1
  • (no location specified)
Nov 9, 2021

Advanced or Metastatic NSCLC Trial in Worldwide (TAS-114, S-1)

Completed
  • Advanced or Metastatic Non-small Cell Lung Cancer
  • Loma Linda, California
  • +29 more
Nov 24, 2021

Resected Pancreatic Cancer, Pancreatic Cancer, Adjuvant Chemo Trial in Linkou, Tainan, Taipei (S-1)

Terminated
  • Resected Pancreatic Cancer
  • +2 more
  • S-1
  • Linkou, Taiwan
  • +3 more
Nov 22, 2021

Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers Trial in Taipei (Oxaliplatin, Albumin-Bound Paclitaxel

Completed
  • Gastric Cancer in Situ
  • +2 more
  • Taipei, Taiwan
    Taiwan Cooperative Oncology Group, National Health Research Inst
Apr 5, 2022

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Wuhan, Hubei, China
  • +2 more
Jan 16, 2023

Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction Trial in München (S-1)

Completed
  • Adenocarcinoma,Stomach
  • Adenocarcinoma, Esophagogastric Junction
  • S-1
  • München, Bayern, Germany
    Klinikum der Universität München, Campus Großhadern
Apr 28, 2021

Metastatic Solid Tumor, NSCLC, Gastric Cancer Trial (RO7496353, Atezolizumab, Capecitabine)

Not yet recruiting
  • Metastatic Solid Tumor
  • +3 more
  • (no location specified)
May 22, 2023

Metastatic Colorectal Cancer Trial in Fuzhou (S-1, Irinotecan, Bevacizumab)

Withdrawn
  • Metastatic Colorectal Cancer
  • S-1
  • +2 more
  • Fuzhou, Fujian, China
    Rongbo Lin
Mar 4, 2021

Nasopharyngeal Carcinoma Trial in Shanghai (S-1)

Completed
  • Nasopharyngeal Carcinoma
  • S-1
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 10, 2021

Colorectal Adenocarcinoma Trial in Fuzhou (S-1, Bevacizumab, Capecitabine)

Withdrawn
  • Colorectal Adenocarcinoma
  • S-1
  • +2 more
  • Fuzhou, Fujian, China
    Rongbo Lin
Mar 4, 2021

Hepatocellular Carcinoma Trial in Hangzhou (Sorafenib, S-1, Oxaliplatin)

Withdrawn
  • Hepatocellular Carcinoma
  • Hangzhou, China
    First affiliated hospital, Zhejiang University
Feb 12, 2021

Esophageal Cancer, Chemoradiotherapy, Nimotuzumab Trial in Beijing (Radiotherapy, Nimotuzumab, S-1)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Radiotherapy
  • +2 more
  • Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Oct 21, 2021

Gastric Cancer, Neoadjuvant Therapy Trial in Beijing (radiation, drug, procedure)

Recruiting
  • Gastric Cancer
  • Neoadjuvant Therapy
  • SIB-IMRT
  • +3 more
  • Beijing, China
    Department of Radiation Oncology, Cancer Hospital, Chinese Acade
Jan 20, 2022

Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (Camrelizumab, Pyrotinib, Capecitabine)

Not yet recruiting
  • Gastric Neoplasms
  • Gastroesophageal Junction Adenocarcinoma
  • Shanghai, China
    270 Dongan Road, Fudan University Shanghai Cancer Center
Oct 27, 2021

Pan-tumor Trial in Japan, Korea, Republic of, Taiwan (ONO-4538, oxaliplatin, S-1)

Recruiting
  • Pan-tumor
  • Matsuyama, Ehime, Japan
  • +21 more
Feb 27, 2022

Gastric Cancer, Perioperative, Sintilimab Trial in Tianjin (Sintilimab, S-1, Oxaliplatin)

Recruiting
  • Gastric Cancer
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Aug 25, 2021

Esophageal Cancer, Chemoradiation Trial in Hangzhou (Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1)

Completed
  • Esophageal Cancer
  • Chemoradiation
  • Radiotherapy 54 Gy
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2020

Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Japan, Korea, Republic of, Taiwan

Completed
  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Akashi, Japan
  • +33 more
Feb 23, 2022

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (SMART, DDP, S-1)

Completed
  • Esophageal Squamous Cell Carcinoma
  • SMART
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Sep 2, 2020